Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Ibotenic Acid Toxicity in Mice: Dose and Time
2026-10-09
A 2026 study in Toxin Reviews provides a structured in vivo assessment of ibotenic acid toxicity in mice across dose and observation time. Its findings connect behavioral changes, transient biochemical disruption, early c-fos activation, and reduced Nissl bodies, while also showing why these markers should not be interpreted as direct evidence of human neurodegenerative disease.
-
Amikacin Sulfate: From MIC to Granuloma
2026-10-08
Explore how Amikacin Sulfate acts as an aminoglycoside antibiotic and why granuloma-directed delivery could reshape research on non-tuberculous mycobacterial infections. This evidence-focused analysis separates established mechanism, mouse-model findings, and translational limitations.
-
GDC-0941: Research Context and Evidence Boundaries
2026-10-08
A source-grounded overview of GDC-0941 as a PI3K inhibitor, covering its reported biochemical profile, conceptual oncology applications, evidence provenance, comparison with recent pancreatic cancer research, and limits on interpretation.
-
Cinoxacin: From UTI Activity to Evidence Design
2026-10-07
Cinoxacin is a quinolone antibiotic with a historically defined Gram-negative activity profile. This article reframes its value for urinary tract infection research, bacterial prostatitis research, and antibiotic resistance studies through evidence design, pharmacology, and applicability limits.
-
Difloxacin HCl: An Evidence-Bound Research Map
2026-10-07
Difloxacin HCl is a quinolone antimicrobial antibiotic with distinct research applications in bacterial DNA replication inhibition and multidrug resistance reversal. This evidence-bound guide separates established mechanisms from exploratory interpretation and uses mitotic checkpoint research to clarify how mechanistic claims should be evaluated.
-
Acetoacetic Acid Sodium Salt: Evidence Guide
2026-10-06
Acetoacetic acid sodium salt, also called sodium 3-oxobutanoate, is a sodium-form ketone body metabolite used to frame questions in energy metabolism research. Vendor specifications establish chemical identity and handling information, while peer-reviewed ketone-body literature supports biological relevance but does not establish clinical efficacy for the product.
-
Malate, Metabolic Flux, and Translational Immunology
2026-10-06
Malate is more than a TCA-cycle metabolite: it is a context-sensitive lens on mitochondrial redox, metabolic flux, and tumor–immune communication. This thought-leadership analysis connects malate biology with recent findings on PDHA1 succinylation and macrophage immune escape in cholangiocarcinoma while defining the evidence boundaries for translational research.
-
Canagliflozin: Reading a Negative mTOR Result
2026-10-05
Canagliflozin hemihydrate is best understood through the distinction between SGLT2 biology and mTOR pathway screening. This article interprets a recent drug-sensitized yeast study, explains what its negative result does—and does not—demonstrate, and outlines evidence-aware applications in metabolic research.
-
EGCG Nanoparticles Enhance FLASH Radiotherapy
2026-10-05
A 2026 study reports that functionalized, self-assembled epigallocatechin gallate nanoparticles, termed BENPs, can sensitize 4T1 tumor models to FLASH radiotherapy while promoting antitumor immune responses. The work connects enhanced radiation-associated oxidative and DNA damage with tumor control and immune remodeling, but its translational relevance remains limited by the preclinical model and the need for independent validation.
-
Plk1 Control of p31comet in Checkpoint Disassembly
2026-10-04
Kaisari et al. identify Polo-like kinase 1 (Plk1) as a regulator that restrains p31comet-dependent disassembly of mitotic checkpoint complexes. Their evidence supports a phosphorylation-based mechanism at p31comet S102, helping explain how cells avoid premature checkpoint inactivation during mitosis while defining important boundaries for interpretation.
-
Plk1 Control of p31comet in Mitotic Checkpoint Exit
2026-10-03
Kaisaria and colleagues identify Polo-like kinase 1 (Plk1) as a regulator that restrains p31comet-driven disassembly of mitotic checkpoint complexes through phosphorylation at serine 102. The findings provide a mechanistic explanation for how cells may prevent premature checkpoint termination while distinguishing this cell-cycle pathway from antimicrobial and drug-resistance applications of Difloxacin HCl.
-
Minocycline HCl in iMSC-EV Assays
2026-10-01
Minocycline HCl can serve as a mechanistic perturbation tool when testing inflammatory signaling, microglial responses, and extracellular-vesicle bioactivity. This workflow combines formulation control, dose-response testing, and scalable iMSC-EV production to distinguish antimicrobial, anti-inflammatory, and cell-survival effects.
-
Tetracycline for Reproducible Cell Assay Workflows
2026-10-01
Learn how Tetracycline (SKU C6589) can be incorporated into microbiological controls and cell-assay workflows without confusing antibacterial activity with mammalian viability. This scenario-based guide covers mechanism, compatibility, preparation, interpretation, storage, and practical vendor selection.
-
Camptothecin Workflows for DNA Damage Research
2026-09-30
Build reproducible DNA damage, apoptosis, autophagy, and adaptive-evolution assays with Camptothecin, a mechanistically defined topoisomerase I inhibitor. This guide pairs concentration and timing strategies with controls that distinguish acute cytotoxicity from persistent genome-stress phenotypes.
-
ROS-Degradable LNPs for Tumor-Selective mRNA Delivery
2026-09-30
Cai and colleagues developed a combinatorial library of thioketal-containing biodegradable lipids to exploit elevated reactive oxygen species in tumor cells. The lead lipid, BAmP-TK-12, supported preferential mRNA expression in cancer cells and enabled delivery of the RAS-cleaving effector DUF5, producing stronger antitumor activity than a small-molecule RAS inhibitor in the reported models.